amodiaquine hydrochloride has been researched along with Parasitemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anstey, NM; Chalfien, F; Hasugian, AR; Kenangalem, E; Marfurt, J; Penttinen, PM; Piera, KA; Price, RN; Purba, HL; Ratcliff, A; Russell, B; Siswantoro, H; Tjitra, E; Wuwung, RM | 1 |
| Clark, JA; Connelly, MC; El Mazouni, F; Furimsky, A; Gow, J; Guiguemde, WA; Guy, RK; Iyer, L; Kyle, DE; Min, J; Mirsalis, J; Parman, T; Phillips, MA; Pradhan, A; Zhang, Y; Zhu, F | 1 |
2 other study(ies) available for amodiaquine hydrochloride and Parasitemia
| Article | Year |
|---|---|
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.
Topics: Adolescent; Age Distribution; Amodiaquine; Animals; Antimalarials; Chloroquine; Confidence Intervals; Drug Resistance; Drug Tolerance; Female; Follow-Up Studies; Humans; Inhibitory Concentration 50; Male; Outpatients; Parasitemia; Plasmodium vivax; Prospective Studies; Recurrence; Rural Health; Time Factors; Treatment Failure; Treatment Outcome | 2009 |
Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.
Topics: Administration, Oral; Animals; Antimalarials; Biological Availability; Female; Hep G2 Cells; Humans; Malaria, Falciparum; Mice; Mice, Inbred ICR; Nuclear Magnetic Resonance, Biomolecular; Parasitemia; Plasmodium falciparum; Quinolines; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Structure-Activity Relationship | 2012 |